Loading…
← CockpitCompetitor Analysis › 002004.SZ Huapont Life Sciences Co., Ltd. Class AOpen in the cockpit ↗

Huapont Life Sciences Co., Ltd. Class A002004.SZCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Agricultural

Chinese company spanning pharmaceuticals and agrochemical/chemical manufacturing, having pivoted from its original pesticide business into life sciences.

Momentum leader 87
Mkt cap
$1.39B
US dollars, full cap
Free float
68%
of shares outstanding
$/day
$19.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+1.5 pp
WACC 5.0%
Hurdle
-10 pp
Req g minus delivered
Close · CNYCN¥4.70
1D+0.9%
1W+7.5%
1M+8.1%
3M+4.0%
6M-5.4%
YTD-1.7%
1Y-5.6%
ATR %2.7%
52w lowhigh22.7% off high

What Huapont Life Sciences does

Chinese company spanning pharmaceuticals and agrochemical/chemical manufacturing, having pivoted from its original pesticide business into life sciences.

Products and services

  • Pharmaceutical products
  • Legacy agrochemical business

Customers

  • Hospitals/pharmacies
  • Agrochemical distributors

Where it sits in the supply chain

  • Health Care
  • Diversified chemicals & pharmaceuticals

What could go wrong

  • Diversified/unfocused business mix

Moat: none. Diversified holding spanning pharma and chemicals without a clear single-business moat.

Headquarters: Wuhan, China · Employees: 11,950

Huapont Life Sciences at a glance

Size Huapont Life Sciences (002004.SZ) is a China Materials company (Chemicals: Agricultural) with a market value of $1.39B, the 1745th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥4.70 on 6 Nov 2026.

Performance Over six months the shares fell 5.4%, against -25.7% for the median peer and -16.4% for the China market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue fell 5.6% over the last twelve months (peer median +9.7%); the operating margin is 11.3% (peer median 7.7%).

Valuation It trades at 1.8× enterprise value to sales against a peer median of 1.6× (10th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.5 points above its cost of capital (5.0% WACC).

Relative performance

70809010011 May 202611 Aug 20266 Nov 2026002004.SZ 96Peer median 74
Six months, rebased to 100: Huapont Life Sciences against the median of its 20 peers (local-currency closes).

Huapont Life Sciences financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥11.1BCN¥11.5BCN¥11.6BCN¥11.5BCN¥13.2B
Revenue growth—-1%+1%-12%—
Gross profitCN¥4.91BCN¥3.92BCN¥3.66BCN¥4.19BCN¥5.06B
EBITDAn/aCN¥2.51BCN¥2.09BCN¥2.26BCN¥2.71B
Net incomeCN¥572MCN¥713M-CN¥299MCN¥302MCN¥433M
Free cash flowCN¥2.09BCN¥1.60BCN¥872MCN¥436MCN¥1.50B
Capital expenditureCN¥541MCN¥638MCN¥956MCN¥1.28BCN¥1.13B
Total debtCN¥7.79BCN¥8.14BCN¥9.74BCN¥9.81BCN¥9.20B

Quarterly statements and history in the cockpit →

Huapont Life Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%0%0022170021701866603299002588DEEPAKFERT002215PARADEEPBAYERCROP000422ATULTATACHEM1722UANSUMICHEM60059698793983002004.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Huapont Life Sciences is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×2×4×0022170021701866603299002588DEEPAKFERT002215PARADEEPBAYERCROP000422EIDPARRYATULTATACHEM1722301665UANSUMICHEM6005969879002004.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Huapont Life Sciences is the large dot.

Capital: growth delivered against growth the price implies

-40%-20%0%+20%+40%-25%0%25%50%002217002170002215BAYERCROPATUL1722UANSUMICHEM6005969879002004.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Huapont Life Sciences is the large dot.

Huapont Life Sciences competitors and peer comparison

How Huapont Life Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Huapont Life Sciences against its 20 peers (data as of 6 Nov 2026)
Measure002004.SZPeer medianRank in peer set
1-month return+8.1%-8.3%highest of 21
6-month return-5.4%-25.7%3rd highest of 21
Distance from 52-week high-22.7%-34.7%4th highest of 21
Revenue growth (TTM)-5.6%+9.7%lowest of 21
Operating margin11.3%7.7%9th highest of 21
EV / Sales1.8×1.6×10th most expensive of 20
Growth the price implies (Req g, 7 yrs)-8.7%0.0%2nd least demanding of 12
Growth delivered (Del g)+1.1%+6.9%2nd lowest of 12
Hurdle (Req g minus delivered)-9.8 pp-3.5 pp6th least demanding of 12
ROIC minus cost of capital+1.5 pp+0.2 pp9th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Huapont Life Sciences 002004.SZChina$1.39B-5%-6%11%1.8×-8.7%+1.1%
Holitech Technology 002217.SZChina$1.41B-58%+17%2%5.1×45.7%-37.1%
Shenzhen Batian Ecological Technique 002170.SZChina$1.44B-29%+3%23%2.1×-8.1%+18.8%
China XLX Fertiliser 1866.HKHong Kong$1.51B-27%+24%8%1.1×n/an/a
Jiang Su Suyan Jingshen 603299.SSChina$1.28B-18%-5%5%2.0×n/an/a
Stanley Agricultural 002588.SZChina$1.27B-33%+3%8%0.8×n/an/a
Deepak Fertilisers and Petrochemicals DEEPAKFERT.NSIndia$1.54B-14%+14%13%1.2×n/an/a
Shenzhen Noposion Crop Science 002215.SZChina$1.25B-23%+12%13%2.1×-3.9%+6.9%
Paradeep Phosphates PARADEEP.NSIndia$1.57B+12%+31%7%1.0×n/an/a
Bayer Cropscience India BAYERCROP.NSIndia$1.58B-28%-5%15%2.7×16.1%+5.9%
Hubei Yihua Chemical Industry 000422.SZChina$1.60B-42%+15%5%1.5×n/an/a
E.I.D.-Parry (India) EIDPARRY.NSIndia$1.21B-24%+16%7%0.3×n/an/a
Atul ATUL.NSIndia$1.63B-26%+18%12%2.0×18.2%+11.0%
Tata Chemicals TATACHEM.NSIndia$1.64B-25%+2%3%1.0×n/an/a
Taiwan Fertilizer 1722.TWTaiwan$1.18B-15%+4%-16%3.1×0.0%+3.5%
CAC Nantong Chemical 301665.SZChina$1.17B-26%+27%13%1.6×-1.7%+11.9%
CVR Partners, LP UANUnited States$1.16B-13%+7%21%2.4×-10.5%+11.6%
Sumitomo Chemical India SUMICHEM.NSIndia$1.74B-34%-3%18%4.8×23.4%+4.1%
Zhejiang Xinan Chemical Industrial 600596.SSChina$1.75B-31%+5%2%1.0×12.4%+3.1%
Migao 9879.HKHong Kong$1.08B+16%+27%8%1.3×-2.8%+23.4%
China BlueChemical 3983.HKHong Kong$1.08B-32%+4%5%n/an/an/a

Questions

Which companies are Huapont Life Sciences's closest peers?
The cockpit's peer set: Holitech Technology (002217.SZ), Shenzhen Batian Ecological Technique (002170.SZ), China XLX Fertiliser (1866.HK), Jiang Su Suyan Jingshen (603299.SS), Stanley Agricultural (002588.SZ), Deepak Fertilisers and Petrochemicals (DEEPAKFERT.NS), Shenzhen Noposion Crop Science (002215.SZ), Paradeep Phosphates (PARADEEP.NS).
Is Huapont Life Sciences expensive compared with its peers?
On ev / sales it trades at 1.8× against a peer median of 1.6×, 10th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Huapont Life Sciences stock performed?
Over six months to 6 Nov 2026 the shares returned -5.4% against -25.7% for the median peer; over one year -5.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.